On Friday, it was announced that Bristol-Myers Squibb (NYSE: BMY) will acquire Turning Point Therapeutics (NASDAQ: TPTX) for $4.1 billion ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE